TFEB and Platelet storage pool disease: In particular, iLBD donors (p = 0.043, Wald Chi-Square: 4.093; B = − 0.665; 95% CI [− 1.308: − 0.021]) and GBA-PD/DLB patients (p = 0.009; Wald Chi-Square: 6.750; B = − 0.927; 95% CI [− 1.627: − 0.228]) showed reduced nuclear TFEB immunoreactivity compared to controls, while the same effect was less pronounced in sPD/DLB cases with advanced Braak stages (p = 0.113; Wald Chi-Square: 2.513; B = − 0.669; 95%CI [− 1.496: 0.158]; Fig. 1i).